Abstract Library

#4397 DNA repair enzyme regulation strategy for enhanced pancreatic neuroendocrine tumour therapy via targeting siRNA-lipid nanoparticles

Introduction: Pancreatic neuroendocrine tumours (panNETs) originate from neuroendocrine cells with high rates of metastasis, rendering many patients’ ineligible for surgical resection. The first-line chemotherapeutic agent temozolomide (TMZ) for metastatic panNETs faces challenges related to resistance, primarily mediated by the DNA repair enzyme O6-methylguanine-DNA methyltransferase (MGMT).

Conference:

Presenting Author: Wang F

Authors: Wang F, Xu J, Xu X, Qin Y, Chen J,

Keywords: Lipid nanoparticle, siRNA, DNA repair enzyme, pancreatic neuroendocrine tumour, temozolomide,

#4150 Uncovering the role of netrins and DCC (deleted in colorectal cancer) in pancreatic neuroendocrine neoplasms (PNEN) tumorigenesis

Introduction: DCC functions as a tumor suppressor and is altered in various tumors, including neuroendocrine neoplasms. Netrin (NTN)-1 serves as the primary ligand for DCC. Operating as a dependence receptor, DCC induces apoptosis without NTN and promotes cell survival in its presence. In some cancers like small cell lung cancer and neuroblastoma, upregulation of NTN-3 rather than NTN-1 has been observed. However, the precise involvement of NTNs and DCC in PNEN remains unclear.

Conference:

Presenting Author: Sela Peremen L

Authors: Sela Peremen L, Telerman A, Peshes Yaloz N, Tirosh A,

Keywords: neuroendocrine, netrin, pancreatic neuroendocrine tumor, dcc,

#3505 DRD2 agonist cabergoline abolished the escape mechanism induced by mTOR inhibitor everolimus in pituitary neuroendocrine tumoral cells

Introduction: The mTOR inhibitor everolimus displays antimitotic effects on diverse neoplasms, including pituitary neuroendocrine ones (PitNETs); however, its effect is reduced by an escape mechanism that increases AKT phosphorylation (p-AKT) leading to survival pathway activation. Dopamine receptor type 2 (DRD2) reduces p-AKT in some non-functioning PitNETs (NF-PitNETs) and in lactotrophs MMQ cells, through a β-arrestin2-dependent mechanism.

Conference:

Presenting Author:

Authors: Mangili F, Esposito E, Treppiedi D, Catalano R, Marra G,

Keywords: pituitary neuroendocrine tumor, everolimus, mTOR/AKT pathway, β-arrestin 2, dopamine receptor type 2, cabergoline,

#3224 MicroRNAs - 193 and -223 alter NET differentiation markers and shape inflammatory response in vitro

Introduction: Future improvements in NETs therapy depend on treatments tailored to tumor cell characteristics, microenvironment and inflammatory status. We recently reported selective downregulation of microRNAs (miRs) -29 and -223 in serum of NET patients, suggesting a possible role in NET disease.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Geisler L, Özdirik B, Mohr R, Knorr J, Tacke F,

Keywords: miR, NET, BON, in vitro, biomarker, inflammation,

#2001 The Anticancer Mechanism of Metformin in Pancreatic Neuroendocrine Tumor Cells

Introduction: Metformin, a widely used antidiabetic drug, has been reported to display potent anticancer properties in various types of cancers. In P-NETs, aryl hydrocarbon receptor-interacting protein (AIP) acts as a tumor suppressor and is up-regulated by the somatostatin analog octreotide.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Lania A

Authors: Vitali E, Piccini S, Boemi I, Brambilla T, Zerbi A,

Keywords: GEP-NET, Metformin, AIP,